Coeptis Therapeutics, Inc. Financing Cash Flow
Coeptis Therapeutics, Inc. reported Financing Cash Flow of $8.22 million for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-08.
Discontinued › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2022-11-08
- Coeptis Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2022-09-30 was $6.03M, a 29.96% decline year-over-year.
- Coeptis Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2022-06-30 was $1.07M, a 77.49% increase year-over-year.
- Coeptis Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2022-03-31 was $1.13M, a 54.73% decline year-over-year.
- Coeptis Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2021-12-31 was -$3.48M, a 1194.68% decline year-over-year.
- Coeptis Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2021 was $8.22M, a 183.41% increase from fiscal 2020.
- Coeptis Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2020 was $2.90M.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 4 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 7 month | Net Cash Provided by (Used in) Financing Activities 8 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 10 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|---|---|---|---|
| 2022-09-30 | $6.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $7.09M derived: sum of 2 quarters · filed 2022-11-08 | $8.22M 10-Q · filed 2022-11-08 | $4.74M derived: sum of 4 quarters · filed 2022-11-08 | ||||
| 2022-06-30 | $1.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-02 | $2.19M 10-Q · filed 2022-08-02 | -$1.28M derived: sum of 3 quarters · filed 2022-08-02 | $7.32M derived: sum of 4 quarters · filed 2022-11-08 | ||||
| 2022-03-31 | $1.13M 10-Q · filed 2022-05-12 | -$2.35M derived: sum of 2 quarters · filed 2022-05-12 | $6.25M derived: sum of 3 quarters · filed 2022-11-08 | $6.85M derived: sum of 4 quarters · filed 2022-11-08 | ||||
| 2021-12-31 | -$3.48M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | $5.13M derived: sum of 2 quarters · filed 2022-11-08 | $5.73M derived: sum of 3 quarters · filed 2022-11-08 | $8.22M 10-K · filed 2022-03-11 | ||||
| 2021-09-30 | $8.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $9.20M derived: sum of 2 quarters · filed 2022-11-08 | $11.69M 10-Q · filed 2022-11-08 | $12.01M derived: sum of 4 quarters · filed 2022-11-08 | ||||
| 2021-06-30 | $601.72K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-02 | $3.09M 10-Q · filed 2022-08-02 | $3.41M derived: sum of 3 quarters · filed 2022-08-02 | |||||
| 2021-03-31 | $2.49M 10-Q · filed 2022-05-12 | $2.80M derived: sum of 2 quarters · filed 2022-05-12 | ||||||
| 2020-12-31 | $317.50K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | $25.70K 10-KT · filed 2021-05-11 | $2.90M 10-K · filed 2022-03-11 | |||||
| 2020-11-30 | $6.70K derived: 10-Q 9 month − 10-Q/A 6 month · filed 2021-01-11 | $21.70K 10-Q · filed 2021-01-11 | ||||||
| 2020-09-30 | $1.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $1.08M derived: sum of 2 quarters · filed 2021-11-15 | $2.58M 10-Q · filed 2021-11-15 | |||||
| 2020-08-31 | $15.00K 10-Q/A · filed 2020-11-23 | |||||||
| 2020-06-30 | $77.50K derived: 10-Q 6 month − 10-Q/A 3 month · filed 2021-08-16 | $1.58M 10-Q · filed 2021-08-16 | ||||||
| 2020-03-31 | $1.50M 10-Q/A · filed 2021-05-18 | |||||||
| 2019-12-31 | $20.00K 10-KT · filed 2021-05-11 | |||||||
| 2019-11-30 | $0.00 10-Q · filed 2021-01-11 | |||||||
| 2019-08-31 | $99.00 10-Q/A · filed 2020-11-23 |